Cardinal Health to acquire Harvard Drug for $1.12bn
This article was originally published in Scrip
Cardinal Health (Dublin, Ohio) is to acquire The Harvard Drug Group (THDG; Livonia, Michigan), a distributor of generic pharmaceuticals, over-the-counter medications and related products, for $1.12bn using cash and debt. THDG is currently owned by Court Square Capital Partners. The transaction, which is slated to close at the start of fiscal year 2016, would add about $0.15 per share to its earnings, said Cardinal Health. As a result of this planned acquisition and the pending acquisition of Cordis, Cardinal Health expects EPS of around $4.75 to $5.05 in fiscal 2016. THDG had revenues of approximately $450m in 2014. There are 450 employees and two distribution facilities included in the transaction.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.